Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients

Completed · Not applicable

Conditions studied: Breast Cancer

In brief

The goal of this clinical research is to learn if an ultrasound contrast agent called OPTISON (perflutren protein type A) is effective in finding sentinel lymph nodes before surgery. Contrast agents can help make ultrasound images more accurate. The sentinel lymph node is the first node that may be the target of cancer cells that spread from the tumor.

Key facts

Study ID

NCT02321527

Run by

M.D. Anderson Cancer Center

People needed

21

Starts

2015-07-01

Expected to finish

2016-05-01

Last updated by the study team

2017-06-20

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• 18 years or older.
• Ipsilateral biopsy-proven invasive breast cancer <5 cm in maximal dimension by Ultrasound or Mammography.
• No abnormal axillary nodes identified on grayscale AUS, or abnormal nodes with benign subsequent FNA biopsy.

You may not qualify if…

• Pregnant or nursing women
• Prior SLN dissection
• Neoadjuvant chemotherapy.
• Prior axillary lymph node surgery.
• Prior history of ipsilateral breast cancer.
• Known or suspected: Cardiac shunts
• Known or suspected: hypersensitivity to perflutren, blood, blood products or albumin
• Known or suspected: hypersensitivity to a prior OPTISON administration

Where it is running

• University of Texas MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.